10 Best Biotech Stocks with Highest Upside Potential
On April 16, reports from J.P. Morgan's biopharma and medtech venture and licensing studies indicated that the capital markets began the year 2026 with selective strength.
Denali Therapeutics Inc. (DNLI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 3,731,695 | $71,648,544 | 0.41% | |
| 2. | Holocene Advisors Brandon Haley | 3,195,429 | $61,352,237 | +2% | 0.15% |
| 3. | Fisher Asset Management Ken Fisher | 2,436,895 | $46,788,383 | -6% | 0.02% |
| 4. | Alyeska Investment Group Anand Parekh | 1,941,123 | $37,269,562 | +126% | 0.11% |
| 5. | Lynx1 Capital Management Weston Nichols | 1,880,303 | $36,101,818 | +9% | 5.71% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.00 | 275,000 | $4,950,000.00 | 19,462,499 | 2017-12-12 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $16.50 | 35,198 | $580,767.00 | 296,833 | 2026-01-06 | Filing | |
| $16.50 | 17,218 | $284,097.00 | 282,828 | 2026-01-06 | Filing | |
| $13.58 | 2,937 | $39,884.46 | 242,346 | 2025-08-12 | Filing | |
| $14.64 | 806 | $11,799.84 | 216,585 | 2025-08-13 | Filing | |
| $13.58 | 2,937 | $39,884.46 | 217,391 | 2025-08-12 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,034,434 | $250,261,131 | 0% | |
| 2. | 12,066,479 | $231,676,397 | 0.24% | |
| 3. | 7,012,974 | $134,649,101 | 0.44% | |
| 4. | 6,272,001 | $120,422,419 | 0% | |
| 5. | 6,147,957 | $118,040,774 | 0% |
News See All
Is Denali Therapeutics (DNLI) the Most Promising Mid-Cap Healthcare Stock Under $50?
On December 11, Wedbush analyst Laura Chico maintained her bullish stance on Denali Therapeutics (NASDAQ:DNLI).
15 Most Promising Mid-Cap Healthcare Stocks Under $50
Traditionally, healthcare stocks have been considered defensive, offering strong immunity to business cycles.
H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results
Fein’s bullish stance followed Denali Therapeutics Inc. (NASDAQ:DNLI)’s Q3 results.
15 Stocks Set to Explode in 2026
While the market figures out whether artificial intelligence is driving the next bubble or the next industrial revolution, a quiet rotation of capital into the next wave of growth leaders outside Big ...
11 Best Future Stocks to Buy Now
Over the past year, investors have poured money into cutting-edge technologies like artificial intelligence and electric cars.
12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
11 Best Gene Therapy Stocks to Buy According to Analysts
Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.
Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In
Since leaving his position as CEO of Amazon in 2021, Jeff Bezos has been quite active.
Hedge Fund Resource Center